

Presentazioni dei clinici e dei ricercatori della Regione Emilia-Romagna all'ASCO Meeting, Chicago, 30 Maggio - 4 Giugno 2025

30 Maggio 2025

- **Abstract Title:** A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209

Session Date/Time: 30/05/2025, 2:45 PM

Oral Abstract Session

Authors: Enrico Franceschi et al, IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy

31 Maggio 2025

- **Abstract Title:** A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS trial

Session Date/Time: 31/05/2025, 9:00 AM

Poster Board Number is 309a

Authors: Clara O. Montagut, Stefano Tamberi, et al, Unità Operativa di Oncologia Medica, Ospedale di Ravenna, Italy

- **Abstract Title:** Prognostic and predictive role of HLA supertypes in pMMR mCRC patients receiving FOLFOXIRI/bev 6 atezolizumab in the AtezoTRIBE study

Session Date/Time: 31/05/2025, 9:00 AM

Poster Board Number is 216

Authors: Daniele Rossini, Roberto Moretto, Francesca Battaglin, Carlotta Antoniotti, Federico Scolari, Francesca Bergamo, Alessandra Russo, Joshua Millstein, Ada Taravella, Stefano Tamberi, et al, Unità Operativa di Oncologia Medica, Ospedale di Ravenna, Italy

- **Abstract Title:** Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study

Session Date/Time: 31/05/2025, 9:00 AM

Poster Board Number is 261

Authors: Martina Carullo, Beatrice Borelli, Daniele Rossini, Chiara Boccaccio, Fabiola Paiar, Piero Bucciatti, Luca Morelli, Piercarlo Rossi, Alessandro Passardi, et al, Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

- **Abstract Title:** Health-related quality of life (HRQoL) with paclitaxel plus ramucirumab (PTX-RAM) switch maintenance versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: A secondary endpoint of the ARMANI phase 3 randomized trial.

Session Date/Time: 31/05/2025, 9:00 AM

Poster Board Number is 350

Authors: Eleonora Cristarella, Giovanni Randon, Sabina Murgioni, Ferdinando De Vita, Samantha Di Donato, Elisa Giommoni, Andrea Spallanzani, et al, Unità Operativa di Oncologia, Policlinico di Modena, Italy

- **Abstract Title:** Phase II assessment of carboplatin with etoposide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)

Session Date/Time: 31/05/2025, 3:00 PM

Oral Abstract Session

Authors: Martin McCabe, Laura Kirton, Maria Khan, Sandra J. Strauss, Claudia Valverde, Cristina Mata Fernandez, Roberto Luksch, Toni Ibrahim, et al, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

- **Abstract Title:** Real-world assessment of breast cancer risk following hormonal therapy in endometriosis: A Global Collaborative Network propensity score matched analysis.

Session Date/Time: 31/05/2025, 1:30 PM

Poster Board Number is 482

Authors: Caterina Gianni et al, Medical Oncology, Breast and Gynecologic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

- **Abstract Title:** Phase III study on atezolizumab versus placebo in adjuvant therapy of pleural mesothelioma patients after pleurectomy/decortication: Preliminary results of the AtezoMeso study

Session Date/Time: 31/05/2025, 1:30 PM

Poster Board Number is 208

Authors: Maria Pagano et al, Oncologia Medica, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Italy

- **Abstract Title:** FiRst-line immunOtherapy with or without chemotherapy versus BRAF plus MEK iNhibitors for patients with BRAFV600E-mutated meTastatic non-small cell lung cancer: the FRONT-BRAF study

Session Date/Time: 31/05/2025, 1:30 PM

Poster Board Number is 8574

Authors: Alessandro Di Federico et al, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

- **Abstract Title:** Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC)

Session Date/Time: 31/05/2025, 1:30 PM

Poster Board Number is 8522

Authors: Enriqueta Felip, Peiwen Kuo, Pilar Garrido, Christos Chouaid, Yvonne Summers, Marcello Tiseo et al, Medical Oncology Unit, University Hospital of Parma, Italy

- **Abstract Title:** Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC)

Session Date/Time: 31/05/2025, 1:30 PM

Poster Board Number is 8599

Authors: Niels Reinmuth, Marina Garassino, Oscar Juan-Vidal, Nicolas Girard, Daniel Haggstrom, Manuel Cobo, Maximilian Hochmair, Yvonne Summers, Terufumi Kato, Marcello Tiseo et al, Medical Oncology Unit, University Hospital of Parma, Italy

- **Abstract Title:** Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study).

Session Date/Time: 31/05/2025, 1:30 PM

Poster Board Number is TPS 8122

Authors: Giulia Pasello, Daniela Scattolin, Fabiana Letizia Cecere, Luana Calabrò, Federica Grosso, Giovanni Ceresoli, Marcello Tiseo et al, Medical Oncology Unit, University Hospital of Parma, Italy

- **Abstract Title:** Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).
- Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC)

Session Date/Time: 31/05/2025, 1:30 PM

Poster Board Number is 8513

Authors: Benjamin Levy, Filippo de Marinis, Laura Bonanno, Adrian Sacher, Quincy Chu, Christina Baik, Paolo Bironzo, Lyudmila Bazhenova, Marcello Tiseo et al, Medical Oncology Unit, University Hospital of Parma, Italy

1 Giugno 2025

- **Abstract Title:** Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316)

Session Date/Time: 1/06/2025, 4:30 PM

Rapid Oral Abstract Session

Authors: Marcello Tiseo et al, Medical Oncology Unit, University Hospital of Parma, Italy

- **Abstract Title:** A real-world analysis of the effectiveness of pembrolizumab by type of associated treatment in patients with metastatic cervical cancer: Added value of bevacizumab

Session Date/Time: 1/06/2025, 9:00 AM

Poster Board Number is 429

Authors: Alberto Farolfi et al, Breast and Gynecologic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

- **Abstract Title:** IMPactMF, Randomized, Open-Label, Phase 3 Trial of Imetelstat Versus Best Available Therapy (BAT) in Patients With Intermediate-2 (INT-2) or High-Risk (HR) Myelofibrosis Relapsed or Refractory (R/R) to Janus Kinase Inhibitors (JAKi)

Session Date/Time: 1/06/2025, 9:00 AM

Poster Board Number is 200a

Authors: John O. Mascarenhas, MD, Claire Harrison, MD, Prithviraj Bose, MD, Jean-Jacques Kiladjian, MD, PhD, Alessandro Lucchesi, et al, Ematologia Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

- **Abstract Title:** Gene-expression-profiling plus integrated multidisciplinary approach to detect new-generation risk-adapted prognostic index in smoldering myeloma and multiple myeloma (GIMPI)

Session Date/Time: 1/06/2025, 9:00 AM

Poster Board Number is 126

Authors: Claudio Cerchione et al, Ematologia Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

- **Abstract Title:** Role of the combination of 3 T whole-body MRI and 18F-FDG PET/CT in the management of multiple myeloma and smoldering myeloma: The new era of imaging

Session Date/Time: 1/06/2025, 9:00 AM

Poster Board Number is 128

Authors: Claudio Cerchione et al, Ematologia Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

- **Abstract Title:** DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.

Session Date/Time: 1/06/2025, 9:00 AM

Poster Board Number 114

Authors: Maria-Victoria Mateos, Pawel Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Ward, P. Joy Ho, Roman Hajek, Kihyun Kim, Meletios Dimopoulos, Claudio Cerchione, et al, Ematologia Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

2 Giugno 2025

- **Abstract Title:** Phase II of sunitinib plus nivolumab in extraskeletal myxoid chondrosarcoma: Results from the GEIS, ISG, and UCL IMMUNOSARC II Study

Session Date/Time: 2/06/2025, 11:30 AM

Rapid Oral Abstract Session

Authors: Nadia Hindi, Emanuela Palmerini, Irene Carrasco-Garcia, Enrique Gonzalezbilla, Claudia Valverde, Sandra Strauss, Toni Ibrahim, et al, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

- **Abstract Title:** Real-world evidence of PARPi-related MDS/AML risk in breast cancer patients: An international collaborative network analysis

Session Date/Time: 2/06/2025, 9:00 AM

Poster Board Number is 128

Authors: Michela Palleschi et al, Breast and Gynecologic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

-
- **Abstract Title:** Phase Prognostic role of estrogen receptor (ER) expression in breast cancer (BC) metastases and its dynamics from primary to metastatic disease: Results from a large multicentric cohort of patients with phenotypically stable ER+(≥10%)/HER2- BC.

Session Date/Time:

Poster Board Number is 1067

Authors Federica Miglietta, Claudio Vernieri, Federico Piacentini, Matilde Cacciatore, Andrea Vingiani, Giuseppe Fotia, Andrea Botticelli, Lorenzo Nicol`e, Gaia Griguolo, Tommaso Giarratano, Davide Massa, Carlo Alberto Giorgi, Giovanni Faggioni, Pietro Napolitano, Marina La Commare, Matteo Fassan, Giancarlo Prunerì, Angelo Paolo Dei Tos, Valentina Guarneri, Maria Vittoria Dieci; Department of Oncology, Hematology, and Respiratory Diseases, Modena University, Modena, Italy;

- **Abstract Title:** Germline evaluation of mismatch repair (MMR) genes in breast cancer patients missing Lynch syndrome criteria: Clinical behavior, preventive paths and therapeutic implications.

Session Date/Time:

Poster Board Number is e22507 Publication Only

Authors: Lorena Incorvaia, Laura Cortesi, Tancredi Didier Bazan Russo, Clarissa Mujacic, Emma Zattarin, Alessandro Perez, Elena Barbieri, maria Concetta Vitale, Isabella Marchi, Valerio Gristina, Lavinia Insalaco, Anna Paola Carreca, Chiara Brando, Nadia Barraco, Antonio Galvano, Daniele Fanale, Giuseppe Badalamenti, Viviana Bazan, Ignazio Ugo Carreca, Antonio Russo; University Hospital Modena, Modena, Italy;

- **Abstract Title:** Phase Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.

Session Date/Time:

Poster Board Number is 1074

Authors: Claudio Vernieri, Maria Vittoria Dieci, Roberta Caputo, Paolo Vigneri, Mario Giuliano, Giuseppe Curigliano, Andrea Botticelli, Rebecca Pedersini, Gianpiero Rizzo, Matteo Lambertini, Marianna Sirico, Marta Piras, Francesco Pantano, Angela Toss, Alessandra Gennari, Monica Giordano, Barbara Tagliaferri, Saverio Cinieri, Alberto Zambelli, Leonardo Provenzano, The PALMARES-2 Study Group Department of Oncology, Hematology, and Respiratory Diseases, Modena University, Modena, Italy;

- **Abstract Title:** G Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with breast cancer: Results from an international cohort study.

Session Date/Time:

Poster Board Number is 10509

Authors: Angela Toss, Eva Blondeaux, Elena Tenedini, Lia Bonamici, Rossella Graffeo, Luca Livraghi, Cynthia Villarreal-Garza, Rinat Bernstein-Molho, Ava Kwong, Judith Balma~na, Hans Wildiers, Elisa Agostinetto, Kelly-Anne Phillips, Katarzyna Pogoda, Tiphaine Renaud, Christine Rousset-Jablonski, Alberta Ferrari, Virginia Delucchi, Carmine De Angelis, Matteo Lambertini; University of Modena and Reggio Emilia, Modena, Italy; University Hospital Modena, Modena, Italy;

- **Abstract Title:** G PARPi effectiveness after CDK4/6i in BRCA1- and BRCA2-associated HR+/HER2- advanced breast cancer: Results from the multicenter real-world PAMBRACA study.

Session Date/Time:

Poster Board Number is 1063

Authors: Emma Zattarin, Antonio Marra, Antonella Palazzo, Gaia Griguolo, Claudio Vernieri, Julian Etessami, Letizia Pontolillo, Arianna Daneri, Matteo De Monte, Ornella Ponzoni, Martina Manni, Federica Domati, Giuseppe Curigliano, Massimo Dominici, Laura Cortesi, Matteo Lambertini, Angela Toss; University of Modena, Modena, MO, Italy; Department of Oncology, Modena University Hospital, University of Modena and Reggio Emilia, Modena, Italy; University Hospital Modena, Modena, Italy;